Insmed Inc (INSM)
23.96
-0.84
(-3.37%)
USD |
NASDAQ |
Apr 19, 15:32
Insmed Enterprise Value: 4.057B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 4.057B |
| April 17, 2024 | 4.262B |
| April 16, 2024 | 4.258B |
| April 15, 2024 | 4.357B |
| April 12, 2024 | 4.421B |
| April 11, 2024 | 4.616B |
| April 10, 2024 | 4.591B |
| April 09, 2024 | 4.534B |
| April 08, 2024 | 4.549B |
| April 05, 2024 | 4.482B |
| April 04, 2024 | 4.426B |
| April 03, 2024 | 4.485B |
| April 02, 2024 | 4.280B |
| April 01, 2024 | 4.343B |
| March 28, 2024 | 4.403B |
| March 27, 2024 | 4.432B |
| March 26, 2024 | 4.387B |
| March 25, 2024 | 4.384B |
| March 22, 2024 | 4.299B |
| March 21, 2024 | 4.286B |
| March 20, 2024 | 4.322B |
| March 19, 2024 | 4.255B |
| March 18, 2024 | 4.256B |
| March 15, 2024 | 4.194B |
| March 14, 2024 | 4.282B |
| Date | Value |
|---|---|
| March 13, 2024 | 4.509B |
| March 12, 2024 | 4.430B |
| March 11, 2024 | 4.396B |
| March 08, 2024 | 4.506B |
| March 07, 2024 | 4.498B |
| March 06, 2024 | 4.531B |
| March 05, 2024 | 4.506B |
| March 04, 2024 | 4.573B |
| March 01, 2024 | 4.542B |
| February 29, 2024 | 4.491B |
| February 28, 2024 | 4.537B |
| February 27, 2024 | 4.715B |
| February 26, 2024 | 4.644B |
| February 23, 2024 | 4.426B |
| February 22, 2024 | 4.406B |
| February 21, 2024 | 4.568B |
| February 20, 2024 | 4.712B |
| February 16, 2024 | 4.742B |
| February 15, 2024 | 4.629B |
| February 14, 2024 | 4.435B |
| February 13, 2024 | 4.311B |
| February 12, 2024 | 4.489B |
| February 09, 2024 | 4.555B |
| February 08, 2024 | 4.603B |
| February 07, 2024 | 4.665B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.073B
Minimum
Mar 23 2020
4.961B
Maximum
Dec 31 2023
2.864B
Average
2.822B
Median
Enterprise Value Benchmarks
| NeuroMetrix Inc | -10.75M |
| Intra-Cellular Therapies Inc | 6.476B |
| Rhythm Pharmaceuticals Inc | 2.016B |
| Amylyx Pharmaceuticals Inc | -237.83M |
| AN2 Therapeutics Inc | -36.14M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -186.06M |
| Revenue (Quarterly) | 83.69M |
| Total Expenses (Quarterly) | 246.26M |
| EPS Diluted (Quarterly) | -1.28 |
| Gross Profit Margin (Quarterly) | 77.96% |
| Profit Margin (Quarterly) | -222.3% |
| Earnings Yield | -22.29% |
| Normalized Earnings Yield | -22.63 |